[1]刘海兵,汪洪雷.超声Finkler评分联合血清CA125、CA724用于卵巢肿瘤良恶性鉴别诊断中的应用价值[J].医学信息,2022,35(20):56-59.[doi:10.3969/j.issn.1006-1959.2022.20.013]
　LIU Hai-bing,WANG Hong-lei.Application Value of Ultrasound Finkler Score Combined with Serum CA125 and CA724 in Differential Diagnosis of Benign and Malignant Ovarian Tumors[J].Journal of Medical Information,2022,35(20):56-59.[doi:10.3969/j.issn.1006-1959.2022.20.013]
点击复制

超声Finkler评分联合血清CA125、CA724用于卵巢肿瘤良恶性鉴别诊断中的应用价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年20期
页码:
56-59
栏目:
论著
出版日期:
2022-10-15

文章信息/Info

Title:
Application Value of Ultrasound Finkler Score Combined with Serum CA125 and CA724 in Differential Diagnosis of Benign and Malignant Ovarian Tumors
文章编号:
1006-1959（2022）20-0056-04
作者:
刘海兵; 汪洪雷
（1.横峰县中医院超声科，江西 横峰 334300；2.上饶市妇幼保健院超声科，江西 上饶 334000）
Author(s):
LIU Hai-bing; WANG Hong-lei
(1.Department of Ultrasound,Hengfeng County Hospital of Traditional Chinese Medicine,Hengfeng 334300,Jiangxi,China;2.Department of Ultrasound,Shangrao Maternal and Child Health Hospital,Shangrao 334000,Jiangxi,China)
关键词:
超声Finkler评分; 血清CA125; 血清CA724; 卵巢肿瘤
Keywords:
Ultrasound Finkler score; Serum CA125; Serum CA724; Ovarian tumors
分类号:
R445.1；R737.31
DOI:
10.3969/j.issn.1006-1959.2022.20.013
文献标志码:
A
摘要:
目的 分析超声Finkler评分联合血清CA125、CA724用于卵巢肿瘤良恶性鉴别诊断中的应用价值。方法 选取我院2018年1月-2021年12月收治的62例卵巢肿瘤患者作为研究对象，评估患者超声Finkler评分并检测血清CA125、CA724水平，分析三项指标在卵巢肿瘤良恶性鉴别诊断中的应用价值。结果 病理检查显示，良性48例、恶性14例；恶性肿瘤患者超声Finkler评分、血清CA125以及CA724水平均高于良性肿瘤患者，差异有统计学意义（P＜0.05）；超声Finkler评分检测显示，良性45例、恶性17例；血清CA125检测显示，良性43例、恶性19例；血清CA724检测显示，良性47例、恶性15例；联合检测显示，良性48例，恶性14例；超声Finkler评分、血清CA125以及CA724诊断灵敏度、特异度以及准确率比较，差异无统计学意义（P＞0.05）；联合检测灵敏度、特异度、准确度高于任意单项检测，差异有统计学意义（P＜0.05）；超声Finkler评分的ROC曲线下面积为0.862（0.772~0.951）；血清CA125的ROC曲线下面积为0.857（0.674~1.000）；血清CA724的ROC曲线下面积为0.808（0.682~0.988）；联合检测的ROC曲线下面积为0.893（0.754~1.000）。结论 超声Finkler评分、血清CA125以及CA724在卵巢肿瘤良恶性鉴别诊断中均具有一定的应用价值，但单独检测存在一定的局限性，联合检测能够有效提高诊断准确率，避免误诊、漏诊等情况，值得临床应用。
Abstract:
Objective To analyze the application value of ultrasound Finkler score combined with serum CA125 and CA724 in the differential diagnosis of benign and malignant ovarian tumors.Methods A total of 62 patients with ovarian tumors admitted to our hospital from January 2018 to December 2021 were selected as the research objects. The ultrasound Finkler score was evaluated and the serum CA125 and CA724 levels were detected. The application value of the three indicators in the differential diagnosis of benign and malignant ovarian tumors was analyzed.Results Pathological examination showed that 48 cases were benign and 14 cases were malignant. The ultrasound Finkler score, serum CA125 and CA724 levels in patients with malignant tumors were higher than those in patients with benign tumors, and the differences were statistically significant (P<0.05). Ultrasound Finkler score showed 45 cases of benign and 17 cases of malignant.Serum CA125 detection showed 43 cases of benign and 19 cases of malignant. Serum CA724 detection showed 47 cases of benign and 15 cases of malignant. Combined detection showed 48 cases of benign and 14 cases of malignant ; there was no significant difference in the diagnostic sensitivity, specificity and accuracy of ultrasound Finkler score, serum CA125 and CA724 (P>0.05). The sensitivity, specificity and accuracy of combined detection were higher than those of any single detection, and the differences were statistically significant (P<0.05). The area under ROC curve of ultrasonic Finkler score was 0.862(0.772-0.951). The area under ROC curve of serum CA125 was 0.857(0.674-1.000). The area under ROC curve of serum CA724 was 0.808(0.682-0.988). The area under ROC curve of combined detection was 0.893(0.754-1.000).Conclusion Ultrasound Finkler score, serum CA125 and CA724 have certain application value in the differential diagnosis of benign and malignant ovarian tumors, but there are some limitations in single detection. Combined detection can effectively improve the diagnostic accuracy and avoid misdiagnosis and missed diagnosis, which is worthy of clinical application.

参考文献/References:

[1]段丽,李菊香,王亚敏,等.经阴道超声、MSCT联合血清CA125、CA724诊断卵巢肿瘤的应用价值探讨[J].中国CT和MRI杂志,2021,19(6):128-130. [2]陈咏宁,张雅迪,陈莉,等.血清CA125、HE4及基于二者的ROMA、 CPH-Ⅰ在卵巢肿瘤良恶性鉴别诊断中的应用价值[J].中国医药导报,2019,16(17):9-12,22.[3]杨淳,张莺莺,程龙.4项凝血指标联合CA125检测对良恶性卵巢肿瘤辅助诊断的价值分析[J].检验医学与临床,2021,18(4):440-442,446. [4]杨艳,张国梅,李红娟,等.超声、CT、MRI联合血清CA125对卵巢肿瘤性质的判断价值[J].实用癌症杂志,2021,36(7):1144-1147,1151.[5]代学华,叶永梅,郭停.CA125、HE4、ROMA对卵巢肿瘤诊断及良恶性鉴别的临床价值[J].临床和实验医学杂志,2018,17(14):1550-1553.[6]马彩叶,刘夏天,李星云,等.彩色多普勒超声评分和血流阻力指数结合糖类抗原125在卵巢肿瘤中的诊断价值[J].中国临床保健杂志,2018,21(2):179-181. [7]赵万成,杨清.CA125联合超声在术前预判交界性浆液性卵巢肿瘤保留生育功能手术可行性的价值[J].现代肿瘤医学,2018,26(20):3281-3284.[8]屈娜,王晓彬.中性粒细胞/淋巴细胞比值、D-二聚体联合CA125对卵巢肿瘤的诊断价值[J].现代肿瘤医学,2020,28(9):1520-1525. [9]乔永明,谢朝阳,代瑞.磁共振联合血清糖类抗原125在诊断鉴别卵巢肿瘤良恶性中的应用[J].实用医院临床杂志,2018,15(1):82-86.[10]费晓璐,毛晓玲,刘榕娟.卵巢肿瘤患者行血清CA125、HE4检测联合超声GI-RADS分类鉴别的价值[J].肿瘤影像学,2019,28(5):335-338. [11]赵倩男.彩色多普勒超声联合肿瘤标志物CA125、CA724在卵巢良恶性肿瘤鉴别诊断中的应用价值[J].中国妇幼保健,2020,35(7):1353-1355. [12]韦金虎.CA125、HE4联合超声检查在卵巢肿瘤中的应用价值[J].检验医学与临床,2019,16(12):1715-1717. [13]曾瑾,祝子范,邓宗科,等.超声和血清RBP4及CA125对卵巢肿瘤的诊断价值分析[J].西南国防医药,2019,29(11):1125-1127. [14]苏媛媛,李静,梁义娟.HE4、CA125和D-dimer检测在卵巢癌早期诊断筛查中的应用价值[J].陕西医学杂志,2018,47(3):368-370. [15]陈念,周凯,胡义刚,等.IOTA简易标准联合RI及CA125对卵巢肿瘤定性诊断临床价值[J].医学影像学杂志,2018,28(5):817-820.[16]Zhang M,Cheng S,Jin Y,et al.Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer[J].Biochim Biophys Acta Rev Cancer,2021,1875(2):188503.[17]凌玲,程文国,傅丹,等.CA125、CA19-9、AFP及CEA在卵巢肿瘤诊断中的临床意义[J].国际检验医学杂志,2018,39(20):2538-2541,2544. [18]周婉,张恒,张葛萍,等.超声联合血清CA125、CA199、CEA检测在卵巢良恶性肿瘤鉴别诊断中的价值[J].中国医师杂志,2020,22(2):245-248,253. [19]焦蕊丽,郑华,徐佳圆,等.三维超声联合HE4和CA125水平检测对卵巢良恶性肿瘤鉴别诊断价值[J].中国医学装备,2021,18(7):88-93. [20]龚时鹏,陈咏宁,张雅迪,等.血清CA125和HE4水平及ROMA、CPH-I模型在鉴别卵巢良恶性肿瘤中的价值对比[J].南方医科大学学报,2019,39(12):1393-1401. [21]曹生亚,李佳,杨洪鹏,等.血清人附睾蛋白4、糖类抗原125和卵巢恶性肿瘤风险模型对卵巢癌鉴别诊断的比较[J].中国基层医药,2020,27(1):11-14. [22]李洁,王晨静,李涵,等. 彩色多普勒超声Finkler评分联合血清糖类抗原125诊断卵巢肿瘤的临床价值[J].实用癌症杂志,2021,36(4):672-675.[23]陈鲜霞,张玉英,马钦风,等.Finkler超声评分、血流参数结合肿瘤标志物检测对良恶性卵巢肿瘤的诊断价值研究[J].中国妇幼保健,2019,34(14):3361-3364. [24]孟以秀,熊林.炎症反应相关指标与CA125对卵巢良、恶性肿瘤鉴别诊断意义[J].中国计划生育学杂志,2019,27(9):1174-1176,1179. [25]朱莉,秦丽,王瑞雅,等.血清CA125、HE4、VEGF及ROMA指数对卵巢癌诊断及预测术后复发的价值[J].广东医学,2021,42(7):796-801. [26]马爱矿,高华丽,王敏,等.HE4、CA125和CA199联合D-二聚体检测在卵巢癌早期诊断中的应用[J].中国肿瘤临床与康复,2019,26(7):793-795. [27]计宏媛,石挥扬,陈婉明.彩色多普勒超声联合血清CA125水平检测对卵巢癌患者的诊断效能[J].中国医师杂志,2019,21(12):1841-1844. [28]张燕,史文雯.血清CA125、HE4及MM P-10联合检测在卵巢癌早期诊断中的临床价值研究[J].陕西医学杂志,2018,47(8):1072-1074.[29]赵伟,郑凤俊,姚秀玲.HE4、CA125、B7-H4、B7-H6及Foxp3+Treg联合检测在卵巢癌中的诊断价值[J].医学临床研究,2018,35(6):1044-1046.

相似文献/References:

[1]翟 蓓,周 洋,周 薇,等.超声检查、磁共振及血清CA125测定诊断 子宫腺肌病的临床评价[J].医学信息,2018,31(11):154.[doi:10.3969/j.issn.1006-1959.2018.11.050]
　ZHAI Bei,ZHOU Yang,ZHOU Wei,et al.Clinical Evaluation of Ultrasonography,Magnetic Resonance Imaging and Serum CA125 in Diagnosis of Adenomyosis[J].Journal of Medical Information,2018,31(20):154.[doi:10.3969/j.issn.1006-1959.2018.11.050]
[2]黄流海,范 婵.血清CA125、经阴道B超检查及CT检查在子宫内膜癌术前评估方面的价值[J].医学信息,2018,31(15):151.[doi:10.3969/j.issn.1006-1959.2018.15.049]
　HUANG Liu-hai,FAN Chan.The Value of Serum CA125,Transvaginal B-ultrasound and CT Examination in Preoperative Evaluation of Endometrial Cancer[J].Journal of Medical Information,2018,31(20):151.[doi:10.3969/j.issn.1006-1959.2018.15.049]
[3]钱自强,李 青,李志芳,等.血清CA125、HE4及ROMA在卵巢肿瘤良恶性诊断中的应用价值[J].医学信息,2020,33(04):175.[doi:10.3969/j.issn.1006-1959.2020.04.059]
　QIAN Zi-qiang,LI Qing,LI Zhi-fang,et al.Application Value of Serum CA125,HE4 and ROMA in the Diagnosis of Benign and Malignant Ovarian Tumors[J].Journal of Medical Information,2020,33(20):175.[doi:10.3969/j.issn.1006-1959.2020.04.059]

更新日期/Last Update: 1900-01-01